Metrics cut 1
- Partnership business growth guidance: no longer expected to reach industry growth in 2026 (previously implied to catch up to industry growth; 2027 under evaluation)
Event Participants
Executives
2 Deepak Arora (Managing Director), Rachid Ayari (Chief Financial Officer)
Analysts
5 Divyaksha Agnihotri (NSE India Ltd), Dr. Kartik Bhané (Bajaj Life Insurance), Nan Rusmik Oza (Nine Rays), Rajkumar Vaddepalli (RK Investments), Yash Lokhandwala (M3 Investment Management)
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Total Income Growth (Q2) | +7% YoY | Driven by 6% sales growth (domestic +8%, export -2%); other operating income from group services (consumer health) |
| H1 Sales Growth | -4% YoY to -2% YoY | Impacted by Q1 transition period with partnership business (safety stock normalization & one-off sales returns agreed in Q1 FY26); export decline from Australia competition |
| Diabetes Business Growth (H1) | +17% YoY | Double-digit growth powered by innovative portfolio (Toujeo, Soliqua); 14% growth in Q2 alone, driven by public sector expansion (70% of growth attributed to this) |
| Partnership Business Growth (Q2) | +2% YoY | Lower than industry; CV/CNS/OAD portfolios with Cipla/Emcure facing aggressive generic competition; management expects closer to market growth in coming quarters |
| Profit Before Tax (Q2) | ₹112 crores | +19% YoY (from ₹94 crores); PBT margin 27% of net sales vs 24% in Q2 FY26 (+300 bps) |
| Profit Before Tax (H1) | -4% YoY | Impacted by Q1 partnership transition one-offs; excluding one-offs, high single-digit growth expected |
| Operating Expenses (H1) | -15% YoY | Cost discipline on employee costs and other Opex without impacting top line; continues as trend |
| Cash Position | +34% growth | Healthy balance sheet; no major risks faced |
Geographic & Segment Commentary
Diabetes Business (Core Growth Driver): Strong momentum with Q2 growth ~14%, H1 growth 17%; innovative portfolio Toujeo and Soliqua leading. Market leadership sustained with ~47% value share in diabetes; basal analog franchise (Lantus + Toujeo) holds 58% value and 61% volume market share. Soliqua growing 16% QoQ despite GLP-1 market erosion. Public sector expansion (CGHS, ESIC, railways, state, army) contributed 70% of diabetes growth through new account additions.
Partnership Business (CV, CNS, OADs with Cipla/Emcure): Q2 growth only 2% YoY, below industry. Q1 FY27 impacted by transition-period one-offs (safety stock build in Q1 FY26 and agreed sales returns). OAD segment with Emcure is meeting market growth; CV and CNS portfolios facing aggressive generic competition. Management confirms partners have standalone teams ensuring no portfolio diversion.
Export Business: Declining 2% in Q2/H1, primarily from Australia market competition on mature products. Offsetting losses through other markets (France, Italy, Turkey, Russia) and Goa site specialization as worldwide manufacturing hub for select products. Awaiting South Africa tender results; insourcing previously outsourced CMO products to increase site volume.
Company-Specific & Strategic Commentary
Diabetes Portfolio Leadership: Strategy of "owning Lantus and growing Toujeo and Soliqua" delivering results; Lantus growing at 6% volume, Toujeo gaining 11% value market share as second-generation basal. Real-world evidence publications (4 between Q4 and Q2) strengthening Indian guidelines positioning for Toujeo and Soliqua.
Public Sector Expansion: 70% of diabetes growth driven by entering new state accounts/care segments with Toujeo and Soliqua; strategy to extend equitable access to innovation. Digital outreach in tier-2/tier-3 markets continuing despite optimization.
Digital & Innovation Initiatives: Working on Bluetooth-enabled devices, AI platforms, and patient support programs to simplify insulin initiation-to-intensification journey. Business cases under evaluation to complement daily insulin therapy. Partnership with parent company for pipeline products ongoing.
CSR Commitments: Ahead of schedule; targeting 600,000+ direct beneficiaries by end of 2026 through Kids and Diabetes in Schools and mobile medical units. New MOU with NHM in Madhya Pradesh; expanding from Lucknow, UP, Maharashtra, Goa.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Partnership Business Growth | Not expected to reach industry growth in 2026; 2027 under evaluation | Working with partners on team reorganization and reinvestment; OAD segment already meeting market growth; competitive intensity remains high |
| Diabetes Business Growth | Expectation to sustain H1 momentum in H2 | Management confident of repeating first-half performance in second half; not committing to specific percentage (10-15% range implied) |
| Operating Expenses | Continued reduction trend | -15% in H1; management to continue optimization without impacting top line or ROI-positive projects |
| Dividend Payout | Minimum at last year's level; expected not lower than past | Final decision with Board; +34% cash growth supports payout sustainability |
| Export Strategy | Offset Australia losses with other markets | Gomma specialization, South Africa tenders, CMO insourcing to support volumes |
Risks & Constraints
| Risk | Context |
|---|---|
| Partnership Business Underperformance | Q2 growth of only 2% significantly below industry; management acknowledges not meeting expectations. Competition in generic CV/CNS markets aggressive. Timeline for recovery uncertain (2026 unlikely, 2027 under evaluation). Mitigation: partner team reorganization, OAD segment showing market-level growth. |
| Novo Nordisk Once-Weekly Insulin | New competitive entrant could impact Lantus/Toujeo; management assesses different patient profiles (once-weekly for initiation-resistant patients vs once-daily for progressive disease). Views as market-expanding rather than share-taking; too early to assess impact. |
| GLP-1 Market Dynamics | Erosions in GLP-1 segment; Soliqua (GLP-1+insulin combo) growing despite this. Management sees GLP-1s as complementary, driving share of voice; insulin market may see higher single-digit growth long-term. |
| Export Market Concentration | Australia competition causing volume losses; dependence on new tenders and market diversification. Mitigation: Goa site specialization, CMO insourcing, new market development. |
| Regulatory/Pricing Environment | Not explicitly discussed in detail; public sector expansion implies pricing sensitivity; competitive generic market pressure in partnership portfolio. |
Q&A Highlights
Partnership Business Growth Concerns
- Question: Why is the partnership business showing persistent anemic growth (2% in Q2, below industry) - is this structural or transient? When will it catch up with industry? (Rajkumar Vedirathan, RK Investments)
- Answer: Q1 impact from safety stock build in Q1 FY26 (primary sales accounting) and one-off sales returns agreed during transition. Q2 is apple-to-apple comparison at 2%. Management acknowledges below expectations but working with partners on reorganization/reinvestment. OAD segment (with Emcure) already meeting market growth. 2026 unlikely to reach industry growth; evaluating for 2027. Partners have standalone teams to prevent portfolio cannibalization. (Rachid Ayari, Deepak Arora)
Diabetes Growth Sustainability & New Segments
- Question: Is 14% growth sustainable for next two quarters? Any plans to enter new segments beyond diabetes? Will dividend payout ratio remain healthy? (Nan Rusmik Oza, Nine Rays)
- Answer: Diabetes is only one focus; cardiovascular and CNS partnerships remain strategically important. India diabetes market (~100 million patients) has significant under-diagnosis opportunity. GLP-1s won't impact insulin demand. Management to "leave no stone unturned" to repeat H1 performance in H2. New product pipeline from parent under discussion (devices, AI platforms). Dividend payout expected to be minimum at last year's level; final decision with Board. (Rachid Ayari, Deepak Arora)
Novo Nordisk Once-Weekly Insulin Threat
- Question: How will Novo's once-weekly basal insulin impact Lantus, Toujeo, Soliqua? Is existing patient base sticky? (Divyaksha Agnihotri, NSE India Ltd)
- Answer: Different patient profiles - once-weekly suits initiation-resistant patients (~1/3 of patients neither on once-daily insulin nor GLP-1s); once-daily sustains progressive disease management. Welcome news for market expansion and share of voice. Toujeo/Lantus with GLP-1 show complementary growth. Public sector expansion will continue supporting access. Too early to comment on major impact; need a quarter to assess momentum. (Deepak Arora)
Insulin Market & GLP-1 Impact
- Question: How has the insulin market grown before vs after GLP-1 generalization? (Dr. Kartik Bhané, Bajaj Life Insurance)
- Answer: GLP-1s have driven Toujeo/Lantus growth through combination therapy; Soliqua's 16% growth attributed to GLP-1 share of voice for patients needing insulin without weight gain. Insulin remains gold standard for Type 1/Type 2 management. Market may see higher single-digit growth with GLP-1s supporting awareness; double-digit growth sustained on our portfolio despite GLP-1. (Deepak Arora)
Export Business Strategy
- Question: What is the current export strategy and outlook? (Dr. Kartik Bhané, Bajaj Life Insurance)
- Answer: Offsetting Australia losses with France, Italy, Turkey, Russia markets. Goa site specialized for worldwide manufacturing of select products (one product already succeeded). Awaiting South Africa tender results. Insourcing CMO-outsourced products to boost site volumes. Export performance challenged by board at each meeting. (Rachid Ayari)
Cash Utilization - Buyback
- Question: Any thoughts on using cash for open market buyback (promoters at ~60%, room to 75%)? (Yash Lokhandwala, M3 Investment Management)
- Answer: Board discussed proposals; buyback not currently in strategy. No commitment on capital allocation decisions. (Rachid Ayari)
Key Takeaway
Sanofi India delivered a strong Q2 FY27 with total income up 7% YoY and PBT up 19% to ₹112 crores, driven by exceptional diabetes business performance (Q2 growth ~14%, H1 growth 17%) powered by Toujeo and Soliqua, with 70% of growth attributed to disciplined public sector expansion. Basal analog franchise maintains leadership at 58% value/61% volume market share. The partnership business remains the key concern at 2% growth in Q2, with management acknowledging it won't reach industry growth in 2026 and evaluating 2027; OAD segment with Emcure already meeting market growth. Strategy centers on maximizing the insulin portfolio, leveraging real-world evidence for guideline positioning, and digital/AI-enabled patient support, while OpEx efficiency (-15% H1) drives margin expansion. Cash position up 34% supports minimum historical dividend payout. Watch points include Novo's once-weekly insulin entry, Australian export competition, and partnership recovery timeline. Management expressed optimism for sustained H2 diabetes momentum with "not leaving any stone unturned" in execution, positioning 2026 as the year of acceleration for the diabetes business unit.